Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influence of sustained-release dexamethasone on intraocular cytokines and retinal vessels in retinal vein occlusion
2012-000800-13Phase 4Completed
- Sponsor
- Department of Ophthalmology, Medical University of Vienna
- Start
- Jan 2013
- Modality
- Small Molecules, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ozurdex in Vein occlusion (RVO), central retinal vein occlusion (CRVO), branch retinal vein occlusion (BRVO) and 1 more, sponsored by Department of Ophthalmology, Medical University of Vienna. Primary endpoint: Intraocular concentrations of cytokines and growth factors. Started Jan 2013; status: completed.
02
Drugs
ozurdex
03
Conditions
Vein occlusion (RVO)central retinal vein occlusion (CRVO)branch retinal vein occlusion (BRVO)hemiretinal vein occlusion (HRVO)
Beyond the preview
Go deeper on 2012-000800-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000800-13.